Reportlinker Adds Triple Analysis: Colorectal Cancer, Lymphoma and ...

NEW YORK, May 23, 2011 /NEWS.GNOM.ES/ ? Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Colorectal Cancer, Lymphoma and Angiogenesis

http://www.reportlinker.com/p0284992/Triple-Analysis-Colorectal-Cancer-Lymphoma-and-Angiogenesis.html?utm_source=NEWS.GNOM.ES&utm_medium=pr&utm_campaign=Pathology

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lymphoma

The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Angiogenesis

The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

This part is based on the following publication:

Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies? pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug?s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451

7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699

8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039

10 Disclaimer 1040

11 Drug Index 1041

12 Company Index 1050

Figures: Includes 6 Figures

Tables: Includes 242 Tables

Total Number of Pages: 1,056

Part II: Lymphoma

5.1 The Scope of this Report 26

6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387

7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636

9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938

11 Disclaimer 939

12 Drug Index 940

13 Company Index 948

Figures: Includes 6 Figures

Tables: Includes 222 Tables

Total Number of Pages: 954

Part III: Angiogenesis

5.1 The Scope of this Report 35

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485

9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211

10 Disclaimer 1212

11 Drug Index 1213

12 Company Index 1221

Figures: Includes 7 Figures

Tables: Includes 300 Tables

Total Number of Pages: 1227

To order this report:

Pathology Industryrel='nofollow'>: Triple Analysis: Colorectal Cancer, Lymphoma and Angiogenesisrel='nofollow'>

Pathology Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

http://www.reportlinker.com

Distributed via NEWS.GNOM.ES

Source: http://business.gnom.es/making-money/reportlinker-adds-triple-analysis-colorectal-cancer-lymphoma-and-angiogenesis/

cerebral palsy hiv the temptations aardvark eve online klm bulls